Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
|Articles|January 2, 2004
- Pharmaceutical Technology-01-02-2004
- Volume 28
- Issue 1
The Bioterrorism Act
Author(s)Arthur J. Falk, PhD
Two FDA final rules issued in response to the Bioterrorism Response Act of 2002 may significantly affect the supply and importation of pharmaceutical excipients.
Advertisement
Articles in this issue
almost 23 years ago
Coprocessed Excipients for Solid Dosage Formsalmost 23 years ago
Manufacturing Execution Systemsalmost 23 years ago
State-of-the-Art Packaging Machinesalmost 23 years ago
January 2004almost 23 years ago
Medicare Bill Contains Significant Changes for Drug Manufacturersalmost 23 years ago
New Supply-Chain Dynamicsalmost 23 years ago
In the Spotlight--February 2004almost 23 years ago
January 2004Advertisement
Related to this article
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Germany’s Medical Biotechnology Sector is Flourishing
2
Formulation Strategies for Next-Generation Multiagonists
3
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
4
First-in-Human Trial Speed: Why FDA Trails China
5